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Abstract
Introduction
Age is one of the most important risk factors for human malignancies, including breast cancer; in
addition, age-at-diagnosis has been shown to be an independent indicator of breast cancer
prognosis. However, except for inherited forms of breast cancer, there is little genetic or
epigenetic understanding of the biological basis linking aging with sporadic breast cancer
incidence and its clinical behavior.
Methods
DNA and RNA samples from matched estrogen receptor (ER)-positive sporadic breast cancers
diagnosed in either younger (age 45 or younger) or older (age 70 or older) Caucasian women
were analyzed by array comparative genomic hybridization (CGH) and expression microarrays.
Array CGH data were analyzed using hierarchical clustering and supervised age cohort
comparisons. Expression microarray data were analyzed using hierarchical clustering and Gene
Set Enrichment Analysis (GSEA); as well, differential gene expression was determined by
conditional permutation, and an age signature was derived using Prediction Analysis of
Microarrays (PAM).
Results
Hierarchical clustering of genome-wide copy number changes in 71 ER-positive DNA samples
(27 younger, 44 older) demonstrated two age-independent genotypes, one with few genomic
changes other than 1q gain/16q loss, and another with amplifications and low level gains/losses.
Age cohort comparisons showed no significant differences in total or site-specific genomic
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breaks and amplicon frequencies. Hierarchical clustering of 5.1K genes variably expressed in
101 ER-positive RNA samples (53 younger, 48 older) identified six transcriptome subtypes with
an apparent age bias (p < 0.05). Samples with higher expression of a poor outcome-associated
proliferation signature were predominantly (65%) younger cases. Supervised analysis identified
cancer-associated genes differentially expressed between the cohorts, with younger cases
expressing more cell cycle genes and >3-fold higher levels of the growth factor amphiregulin
(AREG) and older cases expressing higher levels of four different homeobox (HOX) genes in
addition to ER (ESR1). An age signature validated against two other independent breast cancer
datasets proved to have >80% accuracy in discerning younger from older ER-positive breast
cancer cases with characteristic differences in AREG and ESR1 expression.
Conclusion
These findings suggest that epigenetic transcriptome changes, more than genotypic variation,
account for age-associated differences in sporadic breast cancer incidence and prognosis.
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Introduction
Age is the strongest demographic risk factor for most human malignancies including breast
cancer [1]. About 80% of all breast cancers occur in women over age 50; the 10 year probability
of developing invasive breast cancer rises from less than 1.5% at age 40, to about 3% at age 50
and over 4% by age 70, resulting in a cumulative lifetime risk of 13.2% (1 in 8) and a near 9-fold
higher incidence rate in women over age 50 as compared to their younger counterparts [2, 3].
Despite awareness that breast and other cancers are primarily age-related diseases, molecular and
cellular hypotheses explaining the cancer-aging relationship have only recently emerged and
remain clinically unproven [4]. At the subcellular level, normal human aging has been linked to
increased genomic instability [5, 6], global and promoter-specific epigenetic changes [7, 8], and
altered expression of genes involved in cell division and extracellular matrix remodeling [5, 6].
These associations have led to the hypothesis that the cancer-prone phenotype of an older
individual results from the combined effects of cumulative mutational load, increased epigenetic
gene silencing, telomere dysfunction and altered stromal milieu [9]. Given the worrisome social,
economic, and medical consequences of an aging worldwide population, proposed biological
mechanisms linking cancer with aging must be established in order to develop effective
interventions.
As with normal organs and tissues, tumor biology can also change with aging [10, 11].
For sporadic breast cancer in particular, correlations between patient age-at-diagnosis, tumor
biology and clinical prognosis have long been appreciated if not fully understood [12-16].
Younger age-at-diagnosis (< 45 years) is associated with more aggressive breast cancer
biomarkers including overexpression of ERBB2/HER2 and ERBB1/HER1 growth factor
receptors [13], abnormal p53 expression [13, 15], estrogen receptor negativity [12-16], higher
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nuclear grade and Ki-67 proliferation index [12-14, 16]. However, these breast cancer
biomarkers are also interdependent; in particular, ER expression is inversely correlated with
abnormal p53 [15], overexpression of ERBB2 [15], high Ki-67 and nuclear grade, and poor
patient prognosis [17]. Thus, it remains unclear whether the age-specific biomarker features of
breast cancer reflect the pleotropic background effects of aging on the normal mammary gland or
age-specific differences in breast tumorigenesis; as well, since most age-specific biomarkers
strongly associate with ER status, the effects of aging must be studied in histologically similar
breast cancer phenotypes controlled for ER status.
The molecular and cellular effects of aging on both normal and malignant breast tissue
are superimposed on a continuum of developmental changes that normally occur between
puberty and menopause, heavily influenced by menstrual history and parity. In general, normal
mammary gland ER content (fmol receptor/g tissue) as well as the proportion of ER expressing
(ER-positive) ductal epithelial cells increase with each decade of age and reach a plateau with
menopause at about age 50 [18, 19]. In contrast, breast cancer ER expression continues to rise
beyond menopause, reaching a near 25-fold differential between normal and malignant
mammary gland ER expression in patients by age 70 [18]. Curiously, expression of some ER-
inducible gene markers like progesterone receptor (PR), pS2, Bcl2 and cathepsin D do not show
any significant relationship with age-at-diagnosis [13, 18] while others show increased
expression in breast cancers arising earlier in life [20], suggesting that the effects of aging may in
part be attributed to age-related differences in estrogen (E)-inducible ER pathways. Important in
this regard is the age-related change in PR co-expression within ER-positive breast cancers, since
PR has long been used as a clinical indicator for a functioning ER pathway in tumors likely to
respond to endocrine therapy [21]. Among all ethnic patient groups, ER-positive/PR-negative
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breast cancers show the greatest age-related increase in incidence after age 40 [22]. Potentially
relevant to this ER-positive/PR-negative phenotype is the fact that growth factor activated
pathways down-regulate PR expression [22-25], and that the inverse correlation between
overexpression of the ERBB2 growth factor receptor and PR positivity is only seen in breast
cancers arising after age 40 [26]. Surprisingly, the natural perimenopausal decline in ovarian
produced E serum levels do not fully account for age-related changes in ER-regulated mammary
epithelial pathways, since the marked age-related increase in stromal and epithelial aromatase
expression produces postmenopausal mammary gland E levels that are comparable to those
measured in premenopausal women [27].
To better understand the molecular and cellular influences of aging on breast cancer
biology and clinical behavior, we performed a detailed study on phenotypically similar breast
cancers arising in two disparate patient age groups. DNA and RNA were prospectively extracted
from cryobanked samples of stage- and histology-matched ER-positive breast cancers diagnosed
in either younger (< age 45) or older (> age 70) Caucasian women. These samples were analyzed
by array comparative genomic hybridization (CGH) and high-throughput expression microarrays
to look for genetic and epigenetic differences between the age cohorts. Unsupervised hierarchical
clustering of the combined data from both cohorts was used to look for age biases in clustered
subsets, and this was followed by supervised comparisons between the two cohorts to delineate
potential age-related genomic and transcriptome differences. Finally, a predictive analysis of
microarrays (PAM) performed on the two age cohorts produced an age-specific expression
signature which proved to have >80% predictive accuracy when validated against two other
independent breast cancer datasets.
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Materials and methods
Breast cancer samples extracted for DNA and RNA
Cryobanked breast cancer specimens excised from newly diagnosed Caucasian females were
obtained from the University of California San Francisco (UCSF) Comprehensive Cancer Center
Breast Oncology Program Tissue Core (n = 66) and from the National Cancer Institute (NCI)-
Bari (n = 71), following multi-institutional review board approvals. Tumor specimen selection
criteria included sporadic incidence (no first degree relatives with breast cancer), >50% invasive
cancer cellularity, frozen wet weight of at least 100 mg, ER-positivity (>10% nuclear
immunohistochemical stain), and patient age at diagnosis either ≤ 45 (younger cases) or ≥ 70
(older cases) years. The 66 UCSF cases were all node-negative and predominantly ductal
histology (60/66); 54 were associated with outcome annotation. The 71 NCI-Bari cases were all
ductal histology with mixed nodal status and without any outcome annotation. The two age
cohorts within both tumor sets showed no significant imbalances in stage, grade, PR or ERBB2
status. PR-positivity was defined as >10% nuclear immunohistochemical staining and ERBB2-
positivity as gene amplification.
Cryobanked specimens were pulverized under liquid nitrogen prior to nucleic acid
extraction. DNA was purified from frozen tumor powders using High Pure PCR Preparation Kit
(Roche Diagnostics; Indianapolis, Indiana) and quality verified by gel electrophoresis. Total
RNA was purified using Trizol reagent per manufacturer’s protocol (Invitrogen; Carlsbad, CA);
some RNA samples initially stored in formamide were further purified through RNeasy columns
according to manufacturer’s protocol (QIAGEN; Valencia, CA). All RNA samples were quality
verified on a Bioanalyser (Agilent Technologies; Palo Alto, CA). DNA from all 71 NCI-Bari
specimens were used for array-based CGH analysis; but only 35 of these specimens also yielded
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sufficient RNA for expression microarray analysis. The 35 NCI-Bari RNA samples (RNA
sample set 1) were therefore combined with 66 RNA samples prepared from the UCSF
specimens (RNA sample set 2) to yield 101 total RNA samples (53 younger, 48 older) for
expression microarray analysis.
Array CGH and data processing
Array CGH and data processing were carried out as described in [28]. Test and reference
genomic DNA (500~1000 ng) were labeled with Cy3 and Cy5, respectively, in a random priming
reaction using 25 to 50 µL reaction volumes. The two labeled DNAs together with Cot-1 DNA
(100 µg) were hybridized for 48-72 hours at 37ºC onto arrays of 2,464 BAC clones, each printed
in triplicate (HumArray1.14 and Hum-Array2.0, UCSF Comprehensive Cancer Center
Microarray Core). Data from both array versions were combined only for the BAC clones
present on both; duplicate clones were averaged and the final dataset contained 2,240 unique
BACs. Images were acquired and data processed as previously described [28]. For each tumor,
data were plotted in genome order as the mean log2 ratio of the replicate spots for each clone
normalized to the genome median log2 ratio. Array CGH data were deposited into the public
Gene Expression Omnibus database (GSE8801).
Array CGH data were analyzed using circular binary segmentation [29] with default
parameters to translate intensity measurements into regions of equal copy number as
implemented in the DNAcopy R/Bioconductor package. Missing values were imputed using the
maximum value of two flanking segments, producing smoothed values. The gain and loss status
for each probe was assigned using the mergeLevel procedure [30]. Tumor profiles were clustered
using smoothed imputed data with outliers present; and agglomerative hierarchical clustering
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was performed using Euclidean distance as a similarity measure and the Ward method to
minimized sum of variances to produce compact spherical clusters. Clone-wise comparison of
phenotypic groups was made by t-testing smoothed values and controlling for false discovery
rate (FDR), with an FDR adjusted p-value < 0.05 for significance. Kruskal-Wallis rank sum test
was used to analyze phenotypic associations with the following autosomal genomic parameters:
number of break points and chromosomes with break points, number of amplifications and
chromosomes with amplifications, number of whole chromosome changes and fraction of
genome altered.
The fractions of genome gained and lost were computed for each tumor, and the
frequency of alterations at each clone was computed as the proportion of samples showing an
alteration at that locus. The amplification status for a clone was determined by considering the
width of the segment to which that clone belonged (0, if an outlier) and a minimum difference
between the smoothed value of the clone and the segment means of the neighboring segments. A
clone was declared amplified if it belonged to the segment spanning less than 20 Mb and the
minimum difference was greater than exp(-x3) where x is the final smoothed value for the clone.
This procedure allowed clones with small log2ratio values to be declared amplified if they were
high relative to surrounding clones. To calculate the number of chromosomes with
amplifications, a chromosome was said to be amplified if at least one of its clones was amplified.
Whole chromosome changes were assigned to chromosomes without identified breakpoints if a
chromosomal segment mapped to a gain or loss level. The number of chromosomal break points
was calculated as the number of copy number levels within each chromosome across the genome
minus the number of chromosomes. To calculate the number of chromosomes with break points,
at least one break point per chromosome was necessary.
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Microarray expression profiles and data processing
Total RNA (3-5 µg per sample) was labeled and analyzed using Affymetrix (Santa Clara) HT-
HG_U133A Early Access Arrays with 22.9K probes representing ~13K unique Unigenes.
Analyses were performed by standard Affymetrix procedures within the Lawrence Berkeley
National Lab and Life Science Divison’s Molecular Profiling Laboratory
(http://hta.lbl.gov/HTA/index.html). Probe set measurements were generated from quantified
Affymetrix image files (.CEL files) using the RMA algorithm in Bioconductor R. Array data
was deposited in the public Gene Expression Omnibus database (GSE7378 and GSE8193).
Gene expression values were mean centered, with a low variation filter applied to exclude
probe sets that did not have at least 10 observations exhibiting a two-fold change from the mean.
Filtered probes were annotated (GeneTraffic annotation file, March 2006) and those with
unknown UniGene symbols were omitted, yielding a final significant probe set of 6,632
annotated probes representing 5,109 unique genes. Unsupervised hierarchical clustering of the
mean centered significant probe set was performed using Cluster [31], and visualized with Java
TreeView [32]. Phenotypes (e.g. age cohort, PR and ERBB2 status) of the resulting clusters
were compared by χ2 test.
Gene Set Enrichment Analysis (GSEA) was performed using GSEA software v2.01
(http://www.broad.mit.edu/gsea/) [33] to assess tumor phenotypes (e.g. age cohort, PR or
ERBB2 status) with respect to specific gene signatures including a MAPK regulated gene set
[34], a luminal tumor subtype gene set [35], and a proliferation associated gene set [36]. The
enrichment of all curated gene sets (c2) within the Molecular Signature Database (MSigDB)
[33], satisfying the following gene set size filtering criteria (max = 500; min = 10), were also
evaluated. Ranking of Unigenes within each phenotype was based on a signal-to-noise metric;
 11
and an enrichment score (ES) for each signature was derived as a function of the likelihood of
that gene set being among the most highly ranked genes within the phenotype. For genes
represented by more than one probe, the median expression level of all corresponding gene
probes was used; and the significance of ES was estimated by 1000 random permutations of the
sample labels in the tumor dataset. For gene sets showing statistically significant enrichment
with respect to age cohort (p<0.05), unsupervised clustering was performed on the entire set of
RNA samples using those genes; as well, the outcome association of high versus low gene set
expressors was tested by Kaplan-Meier analysis of the 54 cases with known recurrence events.
A conditional permutation test was performed to identify differentially expressed genes
with respect to age and conditional on the RNA sample sources (NCI-Bari and UCSF). For each
gene, a linear fit model of expression level versus age cohort was adjusted for the categorical
sample source, and a p-value was based on the t-statistic on the slope of age. However, the null
distribution used was not the standard normal but based on permuting the age cohort distribution
within each sample source, which provides an exact test of the conditional independence of age
given sample source. This was expected to control for possible different age effects within each
sample source, and to adjust for potential spurious associations based on the different sample
sources [37]. Reported associations between the differentially expressed genes and either cancer
or aging were determined using the MEDGENE database
(http://medgene.med.harvard.edu/MEDGENE/) [38], entering the following search terms:
Neoplasm, Breast Neoplasms, Carcinomas, Breast Carcinomas, and Aging, Premature.
Functional annotation of the differentially expressed genes was performed by Gene Ontology
(GO) analysis [39]; and significant enrichment for specific biological functional categories (> 5
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probes within a process class, EASE score < 0.05) was identified from the DAVID database
(http://david.abcc.ncifcrf.gov/home.jsp) [39].
An age cohort gene signature was obtained by training Predictive Analysis of
Microarrays (PAM) software (http://www-stat.stanford.edu/~tibs/PAM/) on RNA sample set 2
(UCSF), minimizing cross-validation error for the individual age cohorts. The resulting PAM
classifier was used to predict the age cohort of RNA sample set 1(NCI-Bari). For external
validation purposes, expression microarray data from Miller et al.[40] and Sotiriou et al. [41]
were downloaded from the NCBI GEO database (GSE3494 and GSE2990). ER-positive cases
with age characteristics matching our age cohorts were selected, resulting in 102 cases from the
Miller et al. study and 47 cases from the Sotiriou et al. study. As the training set (RNA sample
set 2) comprised only early stage tumors, PAM validation was also performed on the external
datasets restricted to only ER-positive, node-negative cases (35 from Sotiriou et al., and 64 from
Miller et al.). Since these microarray studies used Affymetrix U133A platforms, probe set
measurements were generated using the RMA algorithm in Bioconductor R and the resulting
data were mapped to our significant gene set by Affymetrix probe identifiers, to which the PAM
classifier was applied. The significance of the prediction accuracy was determined using Fisher
Exact Test.
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Results
Age and ER-positive breast cancer genomic profiles
Array CGH at 1 MB resolution was performed on 71 ER-positive primary breast cancer DNA
samples from the two age cohorts: 27 younger and 44 older cases, matched for stage and
histology (nodal status, grade, PR status). Unsupervised hierarchical clustering of the genome-
wide copy number changes (smoothed log2 ratios), as shown in Figure 1, revealed that these ER-
positive cancers comprise two basic genome aberration patterns that have been previously
characterized from unselected breast cancer collections [28]: a simple genotype with few
genomic copy number changes other than gain of 1q and loss of 16q, and a mixed amplifier
genotype with recurrent amplifications and low level genomic gains and losses. Neither the two
primary dendrogram clusters representing these two basic genotypes, nor any of the secondary
dendrogram clusters, exhibit any bias (p > 0.3, Fisher Exact) with respect to age, nodal or PR
status. Direct comparison of the two age cohorts for multiple array CGH parameters revealed no
significant differences in the number of break points, chromosomes with break points,
amplifications, chromosomes with amplifications, or whole chromosome changes; as well, the
fraction of genome gained, lost or otherwise altered were not significantly different between the
two age cohorts (Supplementary Figure 1). While non-significant trends suggested slightly fewer
oncogene amplifications within the older cohort, overall amplification frequencies for the most
common oncogene loci were as follows: MYC (8q24.2; 27%), CCND1 (11q13.3; 23%), ZNF217
(20q32; 17%), AIB1 (20q13.12; 16%), MDM2 (12q15; 8%), ESR1 (6q25; 7%), ERBB2 (17q12;
7%), and TOPO2A (17q21; 7%).
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Unsupervised analysis of ER-positive breast cancer expression profiles
RNA sample set 1 (35 NCI-Bari RNA samples) and RNA sample set 2 (66 age-matched UCSF
samples) were combined to yield 101 RNA samples from ER-positive breast cancers, arising in
the predefined younger (n = 53) and older (n = 48) age groups, well balanced for tumor size,
nodal involvement, grade, PR and ERBB2 status. Figure 2 shows the unsupervised hierarchical
clustering of these 101 breast cancer cases, based on their gene expression similarity across
nearly 5.1K variably expressed unique genes (6,632 probe sets), into six different transcriptome
clusters of ER-positive breast cancer (groups 1A, 1B, 2A, 2B, 3A, 3B). The four different ESR1
probes on the array defined two primary ESR1-associated probe set clusters, including genes
(e.g. GATA3, KRT8, KRT18) commonly used to define luminal-type breast cancers [35, 36, 42-
44]. There was an average 65-fold range in the ESR1 transcript levels across this entire collection
of 101 breast cancers, with the ESR1-associated probes showing similar variations. The six
different transcriptome clusters showed no significant bias with respect to tumor PR and ERBB2
status; in contrast, two of the clusters were composed primarily of younger cases (64% of group
1A, 81% of group 2B) and one was composed primarily of older cases (68% of group 2A). When
cluster composition with respect to age, PR and ERBB2 status were statistically compared, only
the age cohort distribution was found to be significantly different (χ2 test, p < 0.05). Patient
outcome data were available on 54 (30 young, 24 old) of the 101 cases, scattered evenly among
the six transcriptome clusters. Kaplan-Meier probability curves for recurrence-free survival
(RFS) indicated that younger age and PR-negative status were associated with earlier relapse, but
these outcome differences did not quite reach statistical significance (age: p = 0.09, PR: p = 0.08;
log-rank analyses). However, Kaplan-Meier curves for cases representing each of the six
transcriptome clusters did achieve significant separation (p = 0.025, log rank), with the
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predominantly younger group 2B cases showing the shortest survival (median RFS = 2.5 y) and
the predominantly older group 2A cases showing significantly more prolonged survival (median
RFS = 6.2 y).
Gene set enrichment analysis
Probe sets for the variably expressed genes were subjected to Gene Set Enrichment Analysis
(GSEA) with respect to each age cohort for MAPK regulated genes [34], luminal subtype
markers [35], and a gene proliferation signature [36] (gene signatures in Supplement Table 1).
As shown in Table 1, in addition to comparing the age cohorts, these gene signatures were used
to compare PR-negative vs. PR-positive and ERBB2-negative vs. ERBB2-positive cases. There
was no enrichment of any of the three gene signatures according to tumor PR status; and only the
proliferation signature showed any significant relationship to ERBB2 status, with these
proliferation genes more highly expressed in the ERBB2-positive breast cancer cases (nominal p
= 0.01; adjusted for multiple comparisons, p = 0.02). Neither MAPK up-regulated nor MAPK
down-regulated genes showed any significant relationship with age cohort, PR or ERBB2 status
when multiple gene set testing were taken into account. Luminal markers, commonly used as an
expression array signature for ER-positive breast cancers, showed no significant relationship
with age cohort, ERBB2 or PR status, although there was a non-significant trend for luminal
gene expression to associate with PR-positive cases. Proliferation genes were significantly more
highly expressed in the younger cohort (nominal p = 0.006; adjusted for multiple comparisons, p
= 0.011). Interestingly, of the other 1,176 c2:curated gene sets (passing through the size filter)
similarly evaluated, none showed significant enrichment according to age, tumor PR or ERBB2
status when multiple testing was accounted for although two notable trends were observed: cell
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cycle genes, as annotated by GO (c2:500), were enriched in the younger age cohort (nominal
p=0.006, FWER p=0.118); and early response genes downregulated by enforced expression of a
naturally transforming chimeric HOX developmental gene, NUP98-HOXA9 (c2:934) [45], were
enriched in the older age cohort (nominal p=0.000, FWER p=0.112). As shown in Figure 3A,
when the proliferation genes were used to perform unsupervised hierarchical clustering of the
101 cases, two comparably sized subsets were identified. The subset with more highly expressed
proliferation genes contained most of the younger age cases (34/52) and all but one of the
ERBB2-positive cases (χ2, p < 0.05). These proliferation genes were also used to dichotomize
the 54 cases with known clinical outcome; as shown in the Kaplan-Meier curves in Figure 3B,
cases with more highly expressed proliferation genes exhibited significantly worse RFS survival
(p = 0.002, log rank).
Differential gene expression between age cohorts
A conditional permutation strategy was used to identify 75 unique genes (84 probe sets)
differentially expressed between younger and older cohorts (FDR p<0.05), listed in Table 2. Of
these, 24 genes (28 probes) showed increased expression in the younger cohort relative to older
cohort (including GREB1 and AREG), while 51 genes (56 probes) showed increased expression
in the older cohort relative to younger cohort (including ESR1). Interestingly, the E- responsive
genes, GREB1 and AREG, showed higher expression in the younger cohort which showed
significantly lower ESR1 expression. A MEDGENE database search (disease terms
“neoplasms,” “breast neoplasms,” “carcinomas,” or “carcinoma, ductal, breast”) indicated that
29 of the 74 differentially expressed genes had a published first degree association with cancer;
in contrast, none of 74 genes had any published association with aging (disease terms “aging,
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premature”). Gene ontology (GO) analysis was used to determine if the 74 genes differentially
expressed between the age cohorts were enriched for specific biological processes. Several
functional categories were significantly over-represented (EASE score < 0.05) in this gene set
[39], including development, cell cycle, M-phase, morphogenesis and reproduction. As noted in
Table 2, 17 of the genes were associated with development and 9 genes were associated with the
cell cycle, including 5 specifically associated with M-phase.
Defining and validating an age cohort signature in ER-positive breast cancers
PAM was applied to RNA sample set 2 to derive an age cohort signature consisting of 128
unique genes (145 probes), half of which were overexpressed in the younger cohort relative to
the older cohort and half overexpressed in the older cohort relative to the younger cohort (Figure
4A). This signature (Supplement Table 2) was first validated against RNA sample set 1 and then
independently validated against two external breast cancer microarray datasets that included 102
ER-positive from Miller et al. [40] and 47 ER-positive from Sotiriou et al. [41] fitting our age
selection criteria. The PAM-derived age signature correctly identified older from younger ER-
positive cases in all three validation sample sets with comparable accuracy >80% (Figure 4B),
and high statistical certainty (p = 1.3E-7 to 4.2E-12). Interestingly, the majority of errors were
misclassifications of cases from the older cohorts as younger cases. Misclassification bias could
not be associated with either nodal status or outcome differences in the Miller et al. and Sotiriou
et al. datasets; in fact, when these external validation datasets were further restricted to node-
negative cases to match the training set, only a modest increase was observed in predictive
accuracy at the expense of statistical certainty (90%, p = 1.7E-4 for Sotiriou et al.; 86%, p =
1.6E-7 for Miller et al.). ESR1 and AREG were among the 44 genes in common between the age
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signature gene set and the differentially expressed gene set; and, as shown in Figure 4C, age
signature-defined subsets from all four sample dataset showed similar differences in mean
expression levels (log2 intensity) for both ESR1 and AREG. Of note, a PR signature was
similarly derived from RNA sample set 2 (103 probes; Supplement Table 3), but showed only
67% accuracy (p = 0.1) in predicting the PR status of RNA sample set 1.
Discussion
Although there have been numerous studies of clinical factors addressing the relationship
between age-at-diagnosis and breast cancer prognosis [12, 14, 16, 46-48], few studies have
comprehensively investigated the age-dependency of the many well established prognostic breast
cancer biomarkers and none using a prospective study design [13, 18]. Concerned about the
established inverse relationship between ER status and poor-risk biomarker surrogates of breast
cancer proliferation and genomic instability [13, 18], the present study aimed to identify
genomic and transcriptome changes associated with aging using DNA and RNA prospectively
collected from stage- and histology-matched ER-positive breast cancers from younger (< age 45)
and older (> age 70) women, analyzed by array CGH and high-throughput expression
microarrays. Similar bioinformatics-based approaches have been used to characterize aging
effects in human fibroblasts [5, 6], lymphocytes [5] and myoblasts [49]; however, comparable
efforts to investigate aging influences on human cancer biology have not been reported.
Moreover, while ER-positive breast cancers have been well studied as a subgroup within
unselected breast cancer phenotypes using array CGH [28, 50] or expression profiling [35, 36,
42-44], the present study represents the largest reported to date using these powerful techniques
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to subset ER-positive breast cancers, while employing a statistical design powered to detect age-
specific differences.
Array CGH analysis of 71 DNA samples confirmed that our ER-positive breast cancers
were composed of two basic genotypes [28]: a simple subtype characterized by few genomic
copy number changes other than gain of 1q and loss of 16q, and a mixed amplifier subtype
characterized by recurrent amplifications but otherwise low levels of genomic gains and losses.
A third genomic subtype of breast cancer, referred to as complex, known to be almost
exclusively composed of ER-negative breast cancers [28], was not observed in either of the two
age cohorts studied. Neither the simple nor mixed amplifier genomic subtypes of ER-positive
breast cancer showed any particular age bias. Direct comparison of the two age cohorts for
multiple array CGH parameters also revealed no significant differences in: the fraction of
genome altered, whole chromosome changes, total or site-specific amplicon frequencies.
Although non-significant trends suggested slightly fewer oncogene amplifications within the
older cohort, overall amplification frequencies for the most common oncogenes were as expected
for ER-positive breast cancers [44, 51]: MYC (27%), CCND1 (23%), ZNF217 (17%), AIB1
(16%), MDM2 (8%), ESR1 (7%), ERBB2 (7%), and TOPO2A (7%). Thus, at the level of
genomic resolution (~1MB) achievable by BAC-based array CGH, there appeared to be few if
any genetic differences between ER-positive breast cancers arising in women whose ages differ
by more than 25 years. Future studies employing higher density genomic arrays are warranted to
confirm this conclusion.
Microarray profiling of 101 RNA samples showed an average 65-fold range in ESR1
transcript levels across the entire collection of ER-positive breast cancers, with the older cohort
showing significantly higher ESR1 levels as compared to the younger cohort, consistent with
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earlier biomarker studies [13]. There was the expected close correlation between the ESR1
transcript levels and commonly observed ESR1 co-expressed genes (e.g. GATA3) as well as other
genes (e.g. KRT8, KRT18) that characteristically define luminal-type breast cancer, although this
tumor collection also contained several ERBB2-positive cases (10/101) which are not
characteristically found in microarray-defined clusters of luminal-type breast cancer [35, 36, 42-
44]. Hierarchical clustering of the ~5.1K variably expressed genes also identified six
transcriptome subtypes of ER-positive breast cancer with significant age biases (p < 0.05) but not
associated with differing PR status. Based on relapse-free survival analyses of the 54 cases with
known clinical outcome (30 young, 24 old), there was a trend supporting less favorable
prognosis for the younger age (p = 0.09) and PR-negative cases (p = 0.08). However, the six age-
biased transcriptome clusters showed significantly different relapse-free survival outcomes (p =
0.025, log rank), suggesting that these transcriptome subtypes represent clinically relevant
phenotypes of ER-positive breast cancer. Previous expression array studies analyzing fewer ER-
positive cases have identified no more than two or three subsets of luminal-type breast cancer
[35, 36, 42-44].
Reported gene signatures representing luminal, proliferation and MAPK markers were
tested for their enrichment in one or the other of the age stratified cohorts, and only the
proliferation gene signature showed any significant age bias when multiple testing was
accounted for, being more highly expressed in the younger cohort. This finding is consistent with
earlier studies showing higher tumor grade and proliferation markers (e.g. mitotic index and Ki-
67 positivity) in younger age breast cancer patients [13]. While none of the >1000 curated gene
sets in MSigDB that were similarly evaluated demonstrated any significant age biases when
multiple testing was account for, a trend was observed for enrichment of cell cycle genes in the
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younger cohort cases. Nine genes common to both the GO biological process cell cycle set and
the proliferation signature set (BUB1, CCNB1, CCNE2, CDC25A, CDC7, MAD2L1, MCM4,
ORC6L, PTTG1) were also present in our significant probe set. Among these, four (BUB1,
CCNE2, MAD2L1, ORC6L) have been previously associated with poor prognosis ER-positive
breast cancers in a well-established 70-gene prognostic signature [51]; thus, these are likely
important contributors to the more aggressive tumor characteristics of ER-positive breast cancers
arising in younger patients.
Using only the proliferation gene signature to perform unsupervised hierarchical
clustering of the 101 cases generated two comparably sized ER-positive subsets, one with higher
and another with lower expression of the proliferation genes; the higher expressing subset
contained most of the younger age cases (34/52) and all but one of the ERBB2-positive cases.
When this proliferation signature was also used to dichotomize the 54 cases with known clinical
outcome, the higher expressing cases showed significantly worse disease-free survival as
compared to the lower expressing cases, consistent with reports on the association of a similar
proliferation signature with poor outcome in patients with ER-positive breast cancer [52].
Interestingly, despite a presumed mechanistic link between activation of growth factor receptors,
MAPK signaling and cell proliferation, there was minimal overlap between genes in the reported
MAPK and proliferation signatures, and no significant association was observed between the
MAPK signature, age and ERBB2 positivity.
Despite the observed positive association between ESR1 expression level and older age,
no age association was seen for the luminal gene signature which included ESR1, ESR1-
associated genes, and E-inducible genes. This finding is consistent with our previous report
showing increased breast cancer ER protein with aging without comparably increased levels of
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such E-inducible markers as PR, pS2, Bcl2 and cathepsin D [13], and suggesting reduced E
signaling in breast tumors of older patients. In keeping with these protein biomarker
observations, differential gene expression analysis in the present study did not identify any
known E-inducible genes like TFF1, PGR, IRS1, IGFBP4, PCNA, MYC, CCNA2, or DLEU2 as
being more highly expressed in the older cohort despite higher expression of ESR1 in this cohort.
In contrast, two E-inducible growth-regulating genes, GREB1 and AREG, showed significantly
higher expression levels in the younger cohort, in keeping with a recent study demonstrating a
negative correlation between these E-inducible genes and age [20]. As GREB1 and AREG are
known to induce cell proliferation upon E activation [53, 54], their increased expression in the
younger cohort offers some mechanistic basis for increased proliferative activity and gene
expression in the younger cohort.
Of the 75 unique genes differentially expressed between younger and older cohorts, 24
showed increased expression in younger relative to older cases (including GREB1 and AREG)
while 51 showed increased expression in older relative to younger cases (including ESR1).
Comparison with a well studied E-inducible gene signature set [20] revealed that ~25% (19/75)
of these differentially expressed genes overlapped with known early or late E responsive genes
and thus potentially reflected hormonal changes associated with menopause rather than aging
effects. While two-thirds (13/19) of these potential E responsive genes showed appropriate
directional changes according to cohort menopausal status supporting this possibility, at least
75% of the differentially expressed genes would appear to be independent of menopausal
differences in circulating E levels and, therefore, potentially informative of age-related
differences in ER-positive breast cancer biology. A comprehensive database search confirmed
that at least 40% of these differentially expressed genes have reported direct links with
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malignancy; and while none have reported links with premature aging, one of the differentially
expressed genes (KIF2C) has been previously implicated in aging studies of lymphocytes and
fibroblasts [5], while six others (COBLL1, HPGD, HOXB2, PDE4A, SLC25A12, TP73L) were
recently reported as differentially expressed with age in human skeletal muscle [55]. A search for
annotated enrichment of the differentially expressed genes for specific biological processes (GO
Biological Processes, EASE score < 0.05) indicated that “development” and “cell cycle/M-
phase” were the most overrepresented functional gene categories. In keeping with the GSEA
observation indicating a trend for enrichment of cell cycle associated genes in the younger cohort
cases, differentially expressed cell cycle/M-phase genes (including positive regulators like STK6,
FGFR1, and DLG7) represented 20% (5/25) of all genes overexpressed in the younger cohort but
only 8% (4/51) of those overexpressed in the older cohort. In contrast, the older cohort cases
showed differentially increased expression of negative cell cycle regulators (like SASHI and
RHOB) and four developmentally essential homeobox genes (HOXB2, HOXB5, HOXB6,
HOXB7), the latter finding also in keeping with the GSEA observed trend showing enrichment in
the older cohort of HOX-regulated (NUP90-HOXA9 repressed) genes. Two of the overexpressed
HOXB genes (HOXB6, HOXB7) have been specifically linked to mammary gland development
and are known to be expressed in ER-positive breast cancer cells [56]. HOXB7, in particular, is
known to be dependent on stromal (extracellular matrix) signaling, is transcriptionally
upregulated in breast cancers metastatic to bone (relative to primary tumors), and is thought to
play a role in promoting angiogenesis, growth factor-independent proliferation, and DNA
double-strand break repair, conferring breast cancer resistance to the genome destabilizing
effects of DNA damage [57].
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Predictive analysis of microarrays (PAM) was used to derive an age signature that
consisted of 128 unique genes, including 44 of the 75 differentially expressed genes determined
by our conditional permutation approach. The age signature was independently validated against
two other age-matched ER-positive breast cancer microarray datasets and proved to have >80%
accuracy in distinguishing younger from older ER-positive breast cancer cases. ESR1 and AREG
were among the genes in common between the age signature and the differentially expressed
gene sets; thus it is not surprising that the age signature-defined subsets from the two
independent databases showed similar differences in the mean expression levels of these two
genes as found in our age-defined cohorts. Only 28% of the age signature genes overlap with
known early or late E responsive genes, suggesting that this age signature largely reflects age-
related differences in the phenotype of ER-positive breast cancer rather than differences in
circulating E levels associated with menopausal status. The fact that a PAM-derived PR
signature did not perform well upon validation implies substantial heterogeneity between ER-
positive breast cancers with the same PR status, and possibly indicates that confounding age-
related gene expression changes are of greater biological importance than PR-related gene
expression differences. Misclassification errors using the age signature were more prevalent
among the older cohort cases, also suggesting greater variation in expression of the age signature
genes with aging. Of further interest, the 128 age signature gene set was unable to accurately
subset ER-negative cases identified from the two independent breast cancer datasets [40, 41],
consistent with expression array based conclusions that the biology of ER-positive and ER-
negative breast cancers are fundamentally distinct, and supporting the likelihood that the PAM-
derived age signature incorporates biological profiles specific to ER-positive but not ER-
negative breast cancers.
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Conclusions
This prospectively designed study addresses a pressing need to evaluate molecular and cellular
hypotheses proposed to explain age-related differences in breast cancer incidence and clinical
behavior. It is hard to reconcile the evidence gathered in this study of ER-positive breast cancers
with the more general cancer-aging postulate that the breast cancer-prone phenotype of an older
woman results from genomic instability and age-accumulated mutational loads secondary to
telomeric dysfunction and/or progressive DNA damage [9]. More consistent with the present
evidence is the likelihood that ER-positive breast cancers arising in older relative to younger
women do so by a fundamentally different tumorigenic process, manifested more by epigenetic
transcriptome differences such as those regulated by HOX genes, and less by genomic
differences which were not detected using state-of-the-art BAC-based CGH analyses. More
pronounced expression of cell cycle and proliferation associated genes emerged as a strong
defining feature of ER-positive breast cancers arising in younger women, perhaps even driving
their earlier clinical appearance; this observation is certainly consistent with the more aggressive
clinical nature of early age onset breast cancer. Age cohort study designs of this type are needed
to not only confirm the specific transcriptome differences noted here but also to look for
common age-associated differences in gene classes and functional pathways that may enable us
to generalize about the age-related biological differences driving ER-negative breast
tumorigenesis as well as the many other age-associated epithelial malignancies besides breast
cancer.
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Figure legends
Figure 1.
Unsupervised hierarchical clustering of 71 primary ER-positive breast cancers, diagnosed in
younger (< age 45) or older (> age 70) women, based on genome-wide DNA copy number
aberrations. As previously reported for BAC-based array CGH analyses of human breast cancer
samples [5], columns represent individual tumor samples and rows represent individual genome
probes (BAC clones), ordered by chromosome and genome position with 1pter at the top and
22qter at the bottom. Chromosome p-arms and q-arms are shown as different shades of the same
color (blue = odd numbered chromosomes, yellow = even numbered chromosomes). As
indicated in the color scale below, genome copy number losses are indicated in red and copy
number gains are indicated in green. Yellow dots represent high level genomic amplifications.
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Colored and grey-toned upper bars identify the age cohort, PR, nodal and grade status of the ER-
positive samples in each column. The dendrogram shows unsupervised classification of the 71
samples into two primary clusters and four secondary clusters, with no significant cluster bias
according to age, PR, nodal or grade status (p > 0.3, Fisher Exact).
Figure 2.
Unsupervised hierarchical clustering of 101 primary ER-positive breast cancers, diagnosed in
younger (< age 45) or older (> age 70) women, based on genome-wide microarray profiling of
6,632 variably expressed probes (~5.1K unique genes). Cluster dendrogram defines six different
transcriptome subtypes of ER-positive breast cancers (Group 1A, 1B, 2A, 2B, 3A, 3B), with
significant age biases (p < 0.05) but not biased by PR or ERBB2 status; horizontal colored bars
identify the age cohort, PR and ERBB2 status of the ER-positive samples in each column.
Vertical red-green color scale shows log2 ratios from mean centered gene expression levels.
Magnified views show ESR1-containing (ER-associated) probe sets within the entire cluster
diagram.
Figure 3.
Assessment of ER-positive breast cancer subsets by Gene Set Enrichment Analysis (GSEA) for
specific gene signatures. A. Unsupervised clustering of the 101 primary ER-positive breast
cancers shown in Figure 2 based only on expression of the 71-gene proliferation signature shown
to be significant by GSEA, revealing two major clusters (high and low expressors of
proliferation signature) with significant biases in age and ERBB2 status; horizontal colored bars
identify the age cohort, PR and ERBB2 status of the samples in each column. B. Kaplan-Meier
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plots of recurrence events among the 54 ER-positive cases with known clinical follow-up,
dichotomized by high (red) or low (green) expression of the 71-gene proliferation signature, with
significance determined by log rank analysis.
Figure 4.
Prediction Analysis of Microarrays (PAM)-derived age signature validated against independent
ER-positive breast cancer datasets. A. UCSF RNA sample set 2 (n = 66, younger and older) was
used to train PAM and derive a 145-probe (128 gene) age cohort classifying signature, arranged
in ascending order of the PAM score for cases in the older cohort. B. Actual and signature-
predicted age cohort designations for the validating UCSF RNA sample set 1 (n = 35) and two
external validating datasets restricted to ER-positive cases with identical age cohort
characteristics, Sotiriou et al. [41] and Miller et al. [40]. Prediction accuracies are indicated, with
Fisher’s Exact Test p values for significance. C. Age signature-defined subsets from all four
sample datasets show similar differences in log2 expression levels (mean, + SD) of AREG and
ESR1.
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Table 1.
GSEA results for gene list tested
old over young cohort PR- over PR+ tumors ERBB2- over ERBB2+
tumors
Comparison
Gene Set ES Nominal
P
FWER
P
ES Nominal
P
FWER P ES Nominal
P
FWER P
MAPK up-regulated 0.44 0.05 0.13 0.28 0.49 0.67 0.28 0.46 0.65
MAPK down-regulated -0.36 0.17 0.4 -0.31 0.33 0.57 0.26 0.26 0.68
Luminal Markers 0.31 0.72 0.79 -0.63 0.1 0.15 0.48 0.38 0.57
Proliferation Markers -0.85 0.006 0.011 0.62 0.32 0.38 -0.83 0.01 0.02
Note: Gene sets showing significant enrichment after adjustment for multiple gene set testing (FWER P <0.05) are
highlighted in bold
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Table 2.
Differentially expressed genes between the young and old cohorts
Genes with Higher Expression in the Young Cohort
UniGene Symbol Fold Change
(young/old)
UniGene Name
AREG* 3.12 amphiregulin (schwannoma-derived growth factor)
PRSS2* 2.71 protease, serine, 2 (trypsin 2)
GREB1* 2.34 GREB1 protein
PTHLH* (†) 2.01 parathyroid hormone-like hormone
HPGD** 1.98 hydroxyprostaglandin dehydrogenase 15-(NAD)
SPANXA1 /// SPANXB1 ///
SPANXA2 /// SPANXC** ///
SPANXB2 1.91
sperm protein associated with the nucleus, X-linked, family
member A1 /// SPANX family, member B1 /// SPANX family,
member A2 /// SPANX family, member C /// SPANX family,
member B2
LAMA3 (†) 1.87 laminin, alpha 3
ATP6V1B1** 1.82
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B,
isoform 1 (Renal tubular acidosis with deafness)
S100A2* (†) 1.79 S100 calcium binding protein A2
DIO2** 1.79 deiodinase, iodothyronine, type II
PRSS1*/// PRSS2* /// PRSS3 ///
TRY6 1.77
protease, serine, 1 (trypsin 1) /// protease, serine, 2 (trypsin 2)
/// protease, serine, 3 (mesotrypsin) /// trypsinogen C
FGFR1* (†,§) 1.65 fibroblast growth factor receptor 1
TP73L* (†) 1.60 tumor protein p73-like
PRSS1* 1.59 protease, serine, 1 (trypsin 1)
C20orf59 1.57 chromosome 20 open reading frame 59
DLG7* (‡) 1.56 discs, large homolog 7 (Drosophila)
ELOVL2** 1.52
elongation of very long chain fatty acids (FEN1/Elo2,
SUR4/Elo3, yeast)-like 2
KIF2C* (‡) 1.50 kinesin family member 2C
STK6* (‡) 1.49 serine/threonine kinase 6
UST** 1.47 uronyl-2-sulfotransferase
CDC14A(‡) 1.42 CDC14 cell division cycle 14 homolog A (S. cerevisiae)
ELL3** 1.42 elongation factor RNA polymerase II-like 3
RAD54B** (‡) 1.41 RAD54 homolog B (S. cerevisiae)
ITGA2* (†,§) 1.33 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
Genes with Higher Expression in the Old Cohort
UniGene Symbol Fold Change
(old/young)
UniGene Name
HOXB6* (†) 2.40 homeo box B6
TMC5 2.36 transmembrane channel-like 5
HOXB2** (†) 1.99 homeo box B2
ST6GALNAC5 1.99
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5 /// ST6
(alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5
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KIAA1102 1.82 KIAA1102 protein
PYGL** 1.82
phosphorylase, glycogen; liver (Hers disease, glycogen
storage disease type VI)
TNFSF10* 1.82
tumor necrosis factor (ligand) superfamily, member 10 ///
tumor necrosis factor (ligand) superfamily, member 10
GOLPH2** 1.78 golgi phosphoprotein 2
DSPG3** 1.75 dermatan sulfate proteoglycan 3
GLRX** 1.75 glutaredoxin (thioltransferase)
FLJ20152 1.73 hypothetical protein FLJ20152
GATM** 1.72
glycine amidinotransferase (L-arginine:glycine
amidinotransferase)
ENTPD5* 1.69 ectonucleoside triphosphate diphosphohydrolase 5
SASH1* (‡) 1.69 SAM and SH3 domain containing 1
ITPR1* 1.68 inositol 1,4,5-triphosphate receptor, type 1
ANG** (†,§) ///RNASE4 1.66
angiogenin, ribonuclease, RNase A family, 5 /// ribonuclease,
RNase A family, 4
IQGAP2* 1.63 IQ motif containing GTPase activating protein 2
MANSC1 1.62 MANSC domain containing 1
HOXB5** (†,§) 1.60 homeo box B5
FAH* 1.60 fumarylacetoacetate hydrolase (fumarylacetoacetase)
ARHGDIB** (†) 1.60 Rho GDP dissociation inhibitor (GDI) beta
TAPBPL** 1.59 TAP binding protein-like
CLMN** 1.56 calmin (calponin-like, transmembrane)
ESR1* (†,§, ‡) 1.56 estrogen receptor 1
EFNA1* 1.56 ephrin-A1
COBLL1 1.56 COBL-like 1
P8* (†, M) 1.55 p8 protein (candidate of metastasis 1)
SC5DL 1.52
sterol-C5-desaturase (ERG3 delta-5-desaturase homolog,
fungal)-like
CLEC5A 1.52 C-type lectin domain family 5, member A
SEPT6 (‡) 1.52 septin 6
RHOB* (†,§, ‡) 1.52 ras homolog gene family, member B
CYB5 1.51 cytochrome b-5
PDE4A* 1.50
phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2
dunce homolog, Drosophila)
C21orf25 1.49 chromosome 21 open reading frame 25
CCL3** /// CCL3L1 /// CCL3L3 1.49
chemokine (C-C motif) ligand 3 /// chemokine (C-C motif)
ligand 3-like 1 /// chemokine (C-C motif) ligand 3-like 3
CCDC28A 1.46 coiled-coil domain containing 28A
CALM3 1.46 calmodulin 3 (phosphorylase kinase, delta)
PPFIBP2** 1.46 PTPRF interacting protein, binding protein 2 (liprin beta 2)
DBI** 1.46
diazepam binding inhibitor (GABA receptor modulator, acyl-
Coenzyme A binding protein)
SLC25A12** 1.45
solute carrier family 25 (mitochondrial carrier, Aralar),
member 12
CPM* (†,§) 1.44 carboxypeptidase M
MARCH8 1.43 membrane-associated ring finger (C3HC4) 8
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FLJ20298 1.41 FLJ20298 protein
SLC12A8** 1.40
solute carrier family 12 (potassium/chloride transporters),
member 8
FUCA1* 1.39 fucosidase, alpha-L- 1, tissue
LOC57146 1.38 promethin
RANBP2** 1.36 RAN binding protein 2
HOXB7* (†) 1.36 homeo box B7
PANX1** 1.33 pannexin 1
TGOLN2* 1.31 trans-golgi network protein 2
VWA1** 1.29 von Willebrand factor A domain containing 1
Note 1: * denotes genes showing first degree association with cancer. ** denotes genes showing second
degree association with cancer. Associations were as determined through Medgene database searches
with terms Carcinoma, Ductal Breast Carcinoma, Neoplasms and Breast Neoplasms.
Note 2: Marked in parenthesis are three major GO biological processes found to be enriched among the
75 differentially expressed genes. Enrichment was defined as EASE score < 0.05. (†) denotes genes
involved “development”; (§) denotes genes involved in morphogenesis and (‡) denotes genes involved
in the cell cycle as functionally annotated by DAVID and contributed to the enrichment probability
calculations.
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Additional files
Supplementary Table 1.
Gene Sets used for GSEA. All gene sets were mapped to corresponding Unigene symbols for
input into GSEA software.
Supplementary Table 2.
PAM-derived age signature selected on the bases of minimizing individual cross-validation
errors for both old and young cohorts. The “o score” and “y score” represents a probe’s
contribution to the classification into corresponding age cohorts.
Supplementary Table 3: PAM-derived PR signature selected on the bases of minimizing
individual cross-validation errors for both PR- and PR+ groups. The “neg score” and “pos
score” for each probe denotes its contribution to the classification of the PR status of a particular
tumor.
Supplementary Figure 1.
Comparison between the two age cohorts in array CGH parameters: Number of break points,
Number of chromosomes with break points, Number of amplifications, Number of chromosomes
with amplifications, whole chromosome changes, the fraction of genome gained, fraction of
genome lost and fraction of genome altered.
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